NAP: A novel candidate for AD

I. Gozes*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Peptide-neuroprotective activity scanning of activity-dependent neuroprotective protein (ADNP), a protein essential for brain formation, identified NAP (NAPVSIPQ) as a potent neuroprotective peptide in cell culture. In vivo, NAP provided neuroprotection in an animal model of apolipoprotein E deficiency. Since the lipid carrier, apolipoprotein E has been implicated as a risk factor in AD, and since the knock-out mice exhibit short-term memory deficits that are ameliorated by chronic peptide treatment, this peptide holds promise for future treatment against short-term memory deficits associated with AD. In addition, NAP was efficacious in an animal model of cholinotoxicity, enhancing performance in a water maze test following intranasal administration, an attractive drug application route. Further experiments identified NAP as neurotrophic, stimulating neurite outgrowth. These observations provide a potential basis for rational drug design against neurodegeneration with AL-108 (intranasal administered NAP) as the lead compound.

Original languageEnglish
Title of host publicationResearch and Practice in Alzheimer's Disease
EditorsB. Vellas, E. Giacobini
Number of pages4
StatePublished - 2006

Publication series

NameResearch and Practice in Alzheimer's Disease
ISSN (Print)1284-8360


  • A-beta
  • ADNP
  • ApoE
  • Cholinotoxicity
  • NAP
  • Tau
  • Tubulin
  • VIP


Dive into the research topics of 'NAP: A novel candidate for AD'. Together they form a unique fingerprint.

Cite this